C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins.

1999 Feb;90(2):247-55. Unique Identifier : AIDSLINE MED/99180797
Prohaszka Z; Daha MR; Susal C; Daniel V; Szlavik J; Banhegyi D; Nagy K; Varkonyi V; Horvath A; Ujhelyi E; Toth FD; Uray K; Hudecz F; Fust G; Third Department of Medicine, Semmelweis Medical University,; Budapest, Hungary.


Abstract: Antibodies to solid phase C1q (C1qAb) were determined in 295 serum samples from 132 HIV-infected subjects and in sera from 140 HIV-seronegative healthy individuals as control. An ELISA method applied for the determination of C1qAb in other diseases was used. In part of these sera, other autoantibodies (antibodies reacting with 60-kDa human heat shock protein (hsp60) or mycobacterial hsp65; IgA and IgG class antibodies against the Fab and F(ab')2 moieties of IgG) as well as complement-mediated antibody-dependent enhancement/neutralization (C'-ADE) were also determined. Increased amount of C1qAb was found in HIV-infected subjects as compared with HIV-seronegative controls (P = 0.0138). In 17 of 132 (13.0%) seropositive individuals but only in 7/140 (5.0%) samples from the controls, the amount of C1qAb exceeded the upper limit (95th percentile) of the normal values (P = 0.031). The amount of C1qAb significantly decreased during a follow-up period of 65 months. C1qAb levels were found to strongly correlate to hsp60/65 autoantibodies but did not correlate or only weakly correlated to the amount of anti-Fab or anti-F(ab')2 autoantibodies measured in the same serum samples. Anti-C1q antibodies recognized the solid phase hsp60/65. Three predicted epitope regions of M. paratuberculosis hsp65 were able to bind efficiently C1q antibodies. An inverse correlation was found between C1qAb and C'-ADE, neutralization was more frequent in the sera with detectable C1qAb, whereas sera without C1qAb more likely enhanced HIV infection in vitro. Copyright 1999 Academic Press.
Keywords: JOURNAL ARTICLE Antigens, Bacterial Autoantibodies/*BLOOD Autoantigens Binding Sites Case-Control Studies Chaperonin 60/*IMMUNOLOGY Chaperonins/IMMUNOLOGY Complement 1q/*IMMUNOLOGY Enzyme-Linked Immunosorbent Assay Epitope Mapping Human HIV Infections/*IMMUNOLOGY HIV Seronegativity/IMMUNOLOGY Longitudinal Studies Mycobacterium paratuberculosis/IMMUNOLOGY Prognosis Support, Non-U.S. Gov'tKWDjournalarticleantigens,bacterialautoantibodies/KWDbloodautoantigensbindingsitescase-controlstudieschaperonin60/KWDimmunologychaperonins/immunologycomplement1q/KWDimmunologyenzyme-linkedimmunosorbentassayepitopemappinghumanhivinfections/KWDimmunologyhivseronegativity/immunologylongitudinalstudiesmycobacteriumparatuberculosis/immunologyprognosissupport,non-uKWDsKWDgov't
990630
A9960945

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .